Pharmacokinetics of dimeric dipeptide mimetic of nerve growth factor GC-2 in rats. Part 1. Single and multiple intravascular and extravascular administration. Testing the hypothesis of linearity of pharmacokinetics

The pharmacokinetics of dimeric dipeptide mimetic of nerve growth factor GC-2 in the rat blood plasma after different routes of administration was studied. The drug was administered at dose of 150 mg/kg by single and repeatedly. After single intravenous and intraperitoneal injection, GC-2 was detected for 2 h, its half-life was 0.4 h. GC-2 absolute bioavailability after single intraperitoneal injection was 84.62 %, that indicates the prospect of development its injectable (intramuscularly) dosage form. After 4-fold (1.5 h dosing interval) intraperitoneal injection dose-independent pharmacokinetic parameters of GC-2 practically do not change compared to single administration. This indicates that GC-2 is not accumulated in the body of rats. The hypothesis of the linearity of the pharmacokinetics of GC-2 in the rats blood plasma after single intraperitoneal administration at doses of 50, 100 and 150 mg/kg was tested. It was found that the kinetics of GC-2 in the rat blood plasma is linea.

1. Piradov MA, Maximova MYu, Tanashyan MM. Insult. Poshagovaya instrukcya. Moscow: GEOTAR-Media; 2020. (In Russ.).

2. Liaw N, Liebeskind D. Emerging therapies in acute ischemic stroke. F1000Res. 2020 Jun 5;9:F1000 Faculty Rev-546. DOI: 10.12688/f1000research.21100.1.

3. Seredenin SB, Gudasheva TA. Patent RF — RU2410392C2, 2011. (In Russ.). https://patentimages.storage.googleapis.com/75/fa/e7/322e854039eb0f/RU2410392C2.pdf

4. Gudasheva TA, Logvinov IO, Nikolaev SV, et al. Dipeptide mimetics of different NGF and BDNF loops activate PLC-γ1. Doclady Rossyiskoy Academii nauk. Yauki o zhizni. 2020;494(1):486–490. (In Russ.). DOI: 10.31857/s2686738920050133.

5. Gudasheva TA, Povarnina PY, Antipova TA, et al. Dimeric dipeptide mimetics of the nerve growth factor Loop 4 and Loop 1 activate TRKA with different patterns of intracellular signal transduction. J Biomed Sci. 2015 Dec 8;22:106. DOI: 10.1186/s12929-015-0198-z.

6. Antipova TA, Gudasheva TA, Seredenin SB. In vitro study of neuroprotective properties of a new original nerve growth factor mimetic GC-2. Bull. exp. biol. Med. 2010;150(11):537–540 (In Russ.).

7. Guidelines for conducting preclinical studies of drugs. Part one. Moscow: Grif and K; 2012;865–880. (In Russ.).

8. Miroshnichenko II. Osnovy pharmacokinetiki. Moscow: GEOTAR-Media; 2002. (In Russ.).

9. Antipova TA, Gudasheva TA, Seredenin SB. Novel low-molecular-weight mimetics of the nerve growth factor. Doklady Biochemistry and Biophysics. 2010;434(4):549–552. (In Russ.). DOI: 10.1134/S160767291005011X.

10. Litvin AA, Kolyvanov GK, Blynskaya EV, et al. Quantification of hexamethylenediaminediamide bis-(N-monosuccinyl-L-glutamyl-L-lysine) in the blood plasma by HPLC-MS. Vestnik Moscovsckogo Universiteta. Seria 2. Khimia. 2019;60(3):194-197. (In Russ.).

11. Sergienko VI, Gelliff R, Bondareva IB. Prikladnaya Pharmacokinetika. Moscow: Izdatelstvo RAMN; 2003. (In Russ.).

12. Evans G. A Handbook of Bioanalysis and Drug Metabolism. CRC Press. 2004. 425 p.